Combination Products in Therapy
Drugs, devices, and biologics in combination
Please note: Combination Products in Therapy is no longer accepting submissions. For information on our other journals or any other enquires please contact email@example.com.
Combination Products in Therapy is an international, fully open access, peer-reviewed, rapid-publication journal (peer review in 2 weeks, published 3-4 weeks from acceptance) focused on research around the discovery, development, delivery, and use of therapeutic and diagnostic combination products such as drug/device, biologic/device, drug/biologic, and drug/device/biologic combinations. Articles relating to pharmacoeconomics, outcomes, patient care, management, education, and quality of life are also encouraged.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research papers, drug reviews, case reports, brief reports, and commentaries.
Combination Products in Therapy offers a range of additional features designed to enhance the educational content of the research. Each article is accompanied by a bulleted slide summary for a time-efficient overview of the content. Articles also have the option to include slide sets, videos, animations, and/or enhanced learning resources. These features are published alongside the article on the bespoke journal website: www.combitherapy-open.com
Upon acceptance of your article for publication, you will be required to pay the article open access fee of £175/€200/$260 per printed page. This will enable you to keep the copyright; you are simply assigning the exclusive right to any commercial use of the article to Springer. Your article will be immediately and permanently available with open access.
Combination Products in Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer.
For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/2.5
To view the rest of this content please follow the download PDF link above.